Short answer
Sanara MedTech Inc. (SMTI) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $28M (up 8.9% year over year) with net income of −$452,864.
Q2 2026 key financials · XBRL
- Revenue
- $28M
- +8.9% YoY · +1.2% QoQ
- Net income
- −$452,864
- +77.5% YoY · −198.7% QoQ
- Operating margin
- 6.3%
- Gross margin
- 93.0%
- EPS (diluted)
- −$0.10
- +56.5% YoY · −300.0% QoQ
Source: XBRL data from the Sanara MedTech Inc. (SMTI) Q2 2026 10-Q on SEC EDGAR. USD.
Sanara MedTech Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- THP discontinued in September 2025; single Sanara Surgical reportable segment thereafter
- BIASURGE Vizient contract effective January 1, 2026, expanding contracted hospital access
- Merger expected by year-end with $33.00 cash plus 0.4735 Parent shares per Sanara share
- Near-term headwinds: merger approvals, competition, product acceptance, supply disruptions, and capital requirements
Risk Factors
- Newly added transaction risk: MiMedx merger announced July 29, 2026, subject to uncompleted closing conditions
- Most material update: $9,660,336 termination fee if specified merger-termination conditions occur
- Regulatory and legal risk: Lawsuits could obtain injunctions preventing or delaying merger completion
- Operational risk: Merger uncertainty may increase employee attrition and hinder qualified-personnel recruitment
- Financial risk: Failed merger would leave Sanara bearing substantial advisory, legal, accounting, and related expenses
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Sanara MedTech Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.